Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 -0.61%50 ROE % is 0.09% as of May. 2026, which is 91% below its 10-year median of 1.04. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.01 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 622 Healthcare Providers & Services companies, Pharmarise Holdings ranks worse than 64.15% on this metric.
The historical rank and industry rank for Pharmarise Holdings's ROE % or its related term are showing as below:
TSE:2796'
s ROE % Range Over the Past 10 Years
Min: -5.16 Med: 1.04 Max: 10.15
Current: 1.67
During the past 13 years, Pharmarise Holdings's highest ROE % was 10.15%. The lowest was -5.16%. And the median was 1.04%.
TSE:2796's ROE % is ranked worse than 64.15% of 622
companies
in the Healthcare Providers & Services industry
Industry Median: 5.895
vs TSE:2796: 1.67
Pharmarise Holdings (TSE:2796) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (May. 2026) net income data. The Revenue data used here is two times the semi-annual (May. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Pharmarise Holdings ROE % Related Terms
Pharmarise Holdings ROE % Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (May. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Pharmarise Holdings (TSE:2796) has a ROE % of 0.09% as of May. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharmarise Holdings and its competitors. This is 91% below median its historical median of 1.04. According to the industry distribution chart, Pharmarise Holdings ranks #399 out of 622 companies in the Healthcare Providers & Services industry, placing it in the top 64.1%.
Is Pharmarise Holdings' ROE % too high?
Pharmarise Holdings' current ROE % of 0.09% is 91% below median its 10-year median of 1.04. The Healthcare Providers & Services industry median ROE % is 5.90. Pharmarise Holdings' value of 0.09% is 98.5% below this industry median. Based on the distribution chart, Pharmarise Holdings ranks #399 out of 622 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #399 out of 622 companies for ROE %. This places Pharmarise Holdings in the lower half of its industry. The industry median ROE % is 5.90. Pharmarise Holdings' value of 0.09% is 98.5% below this benchmark. While the company's 10-year median is 1.04 vs. the industry median of 5.90, Pharmarise Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.90, based on 622 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmarise Holdings's current ROE % of 0.09% is 98.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current ROE % is 0.09%, which is 91% below median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current ROE % is 0.09%, which is 91% below median its 10-year median of 1.04 and 98.5% below the Healthcare Providers & Services industry median of 5.90. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current ROE % is 0.09% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
ROE %: 0.09% (91% below median its 10-year median of 1.04)
GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
Industry Position: 98.5% below the Healthcare Providers & Services median (#399 of 622)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
